Here's Why iBio Stock Surged Friday

·1-min read
Here's Why iBio Stock Surged Friday

Shares of iBio (NYSEMKT: IBIO) climbed on Friday after the biotech announced plans to develop an intriguing second-generation vaccine candidate for COVID-19. By targeting the N protein, iBio hopes to develop a vaccine that will be highly effective against new coronavirus variants. "The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine," iBios' chief scientific officer, Martin Brenner, said in a press release.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting